New central stimulants

1961 ◽  
Vol 17 (10) ◽  
pp. 469-470
Author(s):  
R. S. Kapil ◽  
Nitya Anand ◽  
M. M. Vohra ◽  
J. D. Kohli
Keyword(s):  
Central Stimulants

ChemInform Abstract: ANTIDEPRESSANT AGENTS. PART 9. 3,3-DIPHENYLCYCLOBUTYLAMINES, A NEW CLASS OF CENTRAL STIMULANTS

1978 ◽  
Vol 9 (20) ◽  
Author(s):  
B. CARNMALM ◽  
S. RAEMSBY ◽  
A. L. RENYI ◽  
S. B. ROSS ◽  
S.-O. OEGREN ◽  
...  
Keyword(s):  
Antidepressant Agents ◽  
New Class ◽  
Central Stimulants

(+)-AJ 76 and (+)-UH 232: Central stimulants acting as preferential dopamine autoreceptor antagonists

1986 ◽  
Vol 334 (3) ◽  
pp. 234-245 ◽  
Author(s):  
Kjell Svensson ◽  
Anette M. Johansson ◽  
Tor Magnusson ◽  
Arvid Carlsson
Keyword(s):  
Dopamine Autoreceptor ◽  
Central Stimulants ◽  
Autoreceptor Antagonists

Central Stimulants. Cyclized Diphenylisopropylamines

1961 ◽  
Vol 26 (8) ◽  
pp. 2834-2836 ◽  
Author(s):  
STANLEY O. WINTHROP ◽  
LESLIE G. HUMBER
Keyword(s):  
Central Stimulants

scholarly journals Nonmedical Use of Antihistaminergic Anxiolytics and Other Prescription Drugs among Persons with Opioid Dependence

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Disa Dahlman ◽  
Tove Abrahamsson ◽  
Alex H. Kral ◽  
Anders Hakansson
Keyword(s):  
Prescription Drugs ◽  
Opioid Dependence ◽  
Clinical Issue ◽  
Prescription Stimulants ◽  
Drug Classes ◽  
Prescription Drug Use ◽  
Central Stimulants ◽  
Nonmedical Use ◽  
Benzodiazepine Use ◽  
Study Participants

Background. Nonmedical prescription drug use (NMPDU) is an increasing problem, insufficiently studied among people in opioid maintenance treatment (OMT). This study investigates the prevalence of and factors associated with NMPDU for drug classes insufficiently described in opioid-dependent populations, including antihistaminergic anxiolytics and central stimulants.Methods. Study participants were recruited at two OMT clinics in Malmo, Sweden, between October 2014 and December 2015 (N=73) and interviewed about their use, motivations for use, and acquisition and administration of prescription drugs.Results. The majority of the sample reported lifetime NMPDU: 60% for benzodiazepine-like hypnotics (z-drugs), 21% for pregabalin, 19% for stimulants, and 12%–15% for antihistaminergic anxiolytics. Lower age was associated with nonmedical benzodiazepine use (Adjusted Odds Ratio = 0.89; 95% Confidence Interval = 0.82–0.97). Illicit acquisition was reported by 61% of people using z-drugs, 46% of people using pregabalin, and 38% of people using prescription stimulants, but only by 6–10% of people using antihistaminergic anxiolytics.Conclusions. The substantial nonmedical use of pregabalin, z-drugs, and prescription stimulants found in this study suggests that clinicians should prescribe these drugs with great caution. Nonmedical use of antihistaminergic anxiolytics does not seem to be a clinical issue among people in OMT in a Swedish setting, but we propose future studies to monitor their use.

Sign in / Sign up

Export Citation Format

Share Document